High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure
NCT ID: NCT02518828
Last Updated: 2018-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2017-01-31
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Outcomes and Access to Care for Heart Failure Trial
NCT02674438
High Flow Nasal Oxygen and Acute Left Heart Failure
NCT03607357
Use of Oxygen in Heart Failure With Preserved Ejection Fraction
NCT02949531
Feasibility Assessment of the Aquadex FlexFlowTM Ultrafiltration System in Treating Non Hospitalized Heart Failure Patients in Dedicated Heart Failure Centers
NCT01654926
Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output and Filling Pressures in Heart Failure
NCT00595738
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High SpO2
In the high SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range ≥96%
High SpO2
SpO2 range ≥96%
Low SpO2
In the low SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range 90-92%
Low SpO2
SpO2 range 90-92%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High SpO2
SpO2 range ≥96%
Low SpO2
SpO2 range 90-92%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* objective finding of HF (BNP \>400 pg/ml or Chest X-Ray with pulmonary congestion)
* plan to admit with primary diagnosis as HF
* must be able to be randomized within 16 hours of presenting to the ED
* provided written informed consent
Exclusion Criteria
* known prior hypercapnic failure (PaCO2 \>50 mmHg)
* asthma
* primary pulmonary hypertension,
* patients who require urgent positive pressure ventilation or intubation
* patients on \>10 L/min oxygen
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heart and Stroke Foundation of Canada
OTHER
Alberta Innovates Health Solutions
OTHER
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Justin Ezekowitz, MBBCH
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alberta Hospital / Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HiLo-HF- 2 Pilot Trial
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.